[Sideroblastic anemia after prolonged linezolid therapy].
Linezolid is an effective and well-tolerated antibiotic for the treatment of infections caused by Gram-positive pathogens. Some reports have shown that linezolid treatment for more than 2 weeks has been associated with reversible bone marrow suppression, especially thrombocytopenia and anemia. We encountered a case of sideroblastic anemia following prolonged linezolid therapy in a laryngeal cancer patient. He received linezolid therapy for multiple abscesses due to MRSA. Before treatment, the Hb level was 12.5 g/dl and then slowly decreased to 5.9 g/dl for 2 months during treatment. Ringed sideroblasts were detected in the bone marrow. Linezolid was discontinued and the Hb level was slowly increased. This case was considered to reflect a rare complication of linezolid therapy.
Kakimoto
Tsunayuki
T
Department of Hematology, Yokohama Municipal Citizen's Hospital.
Nakazato
Tomonori
T
Miura
Reiko
R
Kurai
Hanako
H
Yamashita
Daisuke
D
Sagara
Yuko
Y
Ishida
Akaru
A
D000038:Abscess / Q000188:drug therapy; D000081:Acetamides / Q000008:administration & dosage / Q000009:adverse effects*; D000368:Aged; D000756:Anemia, Sideroblastic / Q000139:chemically induced*; D000890:Anti-Infective Agents / Q000009:adverse effects*; D006801:Humans; D007822:Laryngeal Neoplasms; D000069349:Linezolid; D008297:Male; D055624:Methicillin-Resistant Staphylococcus aureus; D023303:Oxazolidinones / Q000008:administration & dosage / Q000009:adverse effects*; D013203:Staphylococcal Infections / Q000188:drug therapy
D000081:Acetamides; D000890:Anti-Infective Agents; D023303:Oxazolidinones; D000069349:Linezolid